Following guidance from the MHRA, the medical team at euroClinix will no longer be offering the medication Acomplia (rimonabant) as a method for the treatment of obesity. If you are currently taking this medication, you may stop at anytime. Should you have any queries concerning your treatment do not hesitate to contact your doctor or pharmacist.
As an alternative treatment, euroClinix is offering Xenical (orlistat), which is currently the only prescription weight loss medication approved for sale in the UK.
After extensive research, the MHRA determined that the benefits associated with Acomplia did not outweigh the risks that the medication presented for some patients, and its licence was suspended in the UK, meaning that we are no longer able to prescribe it for weight loss purposes.
Certain psychiatric side effects of Acomplia, most notably depression, were of concern at the time of its approval, but it was deemed safe due to the low percentage of patients who experienced these side effects.
However, in March 2008 the Committee for Medicinal Products for Human Use (CMHP) recommended a review of the data and in May the MHRA alerted healthcare professionals that the risk of depression was higher than previously thought, and therefore Acomplia should be withdrawn from the market.
If you have taken Acomplia and you are looking to continue a weight loss treatment, you may wish to consider taking Xenical, a prescription medication which is proven to help patients lose up to 3% of their body weight in just three months, and an average of 19lb in a year.
While Acomplia acts on the brain to make patients feel fuller, Xenical acts directly on the digestive system by stopping the body from absorbing all the fat which is ingested. The psychiatric risks associated with Acomplia are significantly reduced with the use of Xenical, which after extensive clinical testing has been proven safe and effective for people with a BMI over 30.